Abbott Laboratories Friday won an appeals court ruling stopping Andrx Pharmaceuticals from selling generic versions of its antibiotic Biaxin XL until a patent suit is resolved.
The US Court of Appeals for the Federal Circuit said a trial judge was correct in finding that Abbott was likely to win a patent-infringement suit against Andrx. The trial judge ordered Andrx not to sell copies of the drug while the lawsuit was pending.
Abbott spokesman Jonathon Hamilton told Bloomberg News the company was pleased with the ruling and it “validates the strength of our intellectual property for Biaxin XL.”
Biaxin generated $580 million in global sales in the first nine months of 2006.